Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

Inclusion Criteria:

• Participant has a diagnosis of multiple sclerosis (MS) according to the 2017revision of the McDonald diagnostic criteria and has relapsing forms of multiplesclerosis (RMS): relapsing-remitting MS (RRMS) or secondary progressive MS withactive disease based on recent clinical relapse or MRI lesion activity.

Exclusion Criteria:

• Participant has history of cancer, including solid tumors and hematological exceptfor basal cell cancer of the skin and carcinoma in situ of the cervix, which areexclusionary if they have not been excised and resolved.

• Participant has a history of or currently active primary or secondaryimmunodeficiency.

• Participant has severely compromised cardiac or pulmonary function for which asystemic hypersensitivity reaction to any of the vaccines would pose a significantrisk.

• Participant has received the seasonal influenza vaccine for the 2021/2022 influenzaseason prior to Day 1, or history of influenza vaccine for the 2020/2021 influenzaseason within 6 months prior to Day 1.

• Participant has previous treatment with one of the following medications orinterventions within the corresponding timeframe described as follows:

• Any systemic immunosuppressive treatments with potential overlapping effectswith the baseline of this study. Corticosteroids that are by non-systemicroutes (e.g., topical, inhaled, intra-articular) are allowed.

• History of treatment with IV immunoglobulin (IVIg) or plasmapheresis within 4 weeksprior to Day 1.